Related references
Note: Only part of the references are listed.Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
Wouter T. Zandee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review
D. L. Chan et al.
CLINICAL ONCOLOGY (2018)
NCCN Guidelines® Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines
Manisha H. Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Pamela L. Kunz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Guido Rindi et al.
MODERN PATHOLOGY (2018)
Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation
Ilenia Bartolini et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2018)
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander et al.
CLINICAL CANCER RESEARCH (2017)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
M. Falconi et al.
NEUROENDOCRINOLOGY (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
Timothy J. Hobday et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study
Alexandria T. Phan et al.
LANCET ONCOLOGY (2015)
Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors
James C. Yao et al.
PANCREAS (2015)
Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference
Andrew Kennedy et al.
HPB (2015)
Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment
Athanasios Fountas et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2015)
Sunitinib achieved fast and sustained control of VIPoma symptoms
Louis de Mestier et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
Michel Ducreux et al.
EUROPEAN JOURNAL OF CANCER (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors
Stefano Crippa et al.
SURGERY (2014)
Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma
Jianpeng Chen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Observational Study of Natural History of Small Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors
Sebastien Gaujoux et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Pamela L. Kunz et al.
PANCREAS (2013)
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
K. Oberg et al.
ANNALS OF ONCOLOGY (2012)
Peptide Receptor Radioligand Therapy Is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Simona Grozinsky-Glasberg et al.
CANCER (2011)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy
Staffan Welin et al.
CANCER (2011)
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Ben Lawrence et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy
E. van Schaik et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne E. Pavel et al.
LANCET (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
T. R. Halfdanarson et al.
ANNALS OF ONCOLOGY (2008)
Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours
D O'Toole et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2005)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
MA Kouvaraki et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
